Representative sinusoids for hepatic four-scale pharmacokinetics simulations

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Schwen, Lars Ole ^a   Schenk, Arne ^b,c   Kreutz, Clemens ^d   Timmer, Jens ^d   Rodríguez, María Matilde Bartolomé ^e   Kuepfer, Lars ^b,c   Preusser, Tobias ^a,f  

^a FRAUNHOFER MEVIS   (Germany)

^b BAYER AG   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f JACOBS UNIVERSITY BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; MIDAZOLAM; INSULIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FATTY LIVER; HUMAN; HUMAN TISSUE; INSULIN METABOLISM; LIVER BLOOD FLOW; LIVER NECROSIS; LIVER SINUSOID; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PHARMACOKINETICS; ADULT; ANIMAL; BIOLOGICAL MODEL; CIRCULATION; CYTOLOGY; LIVER; MALE; METABOLISM; PHYSIOLOGY; REGENERATION; VASCULARIZATION;

ADULT; ANIMALS; BLOOD CIRCULATION; CAFFEINE; FATTY LIVER; HUMANS; INSULIN; LIVER; MALE; MICE; MODELS, BIOLOGICAL; PHARMACOKINETICS; REGENERATION;

EID: 84941686968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133653     Document Type: Article

References (149)

1. Kuntz E, Kuntz HD. Hepatology: Textbook and atlas. 3rd ed. Heidelberg: Springer; 2008.
2. Ohtani O, Ohtani Y. Lymph circulation in the liver. The Anatomical Record. 2008; 291(6):643-652. doi:10.1002/ar.20681 PMID: 18484610.
3. Saville BA, Gray MR, Tam YK. Models of Hepatic Drug Elimination. Drug Metab Rev. 1992; 24(1):49- 88. doi:10.3109/03602539208996290 PMID: 1555493.
4. Pang KS, Weiss M, Macheras P. Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts. APPS J. 2007; 9(2):E268-E283.
5. Ierapetritou MG, Georgopoulos PG, Roth CM, Androulakis IP. Tissue-Level Modeling of Xenobiotic Metabolism in Liver: An Emerging Tool for Enabling Clinical Translational Research. Clin Transl Sci. 2009; 2(3):228-237. doi: 10.1111/j.1752-8062.2009.00092.x.
6. Wilkinson GR. Clearance Approaches in Pharmacology. Pharmacol Rev. 1987; 39(1):1. PMID: 3554275.
7. Hoehme S, Brulport M, Bauer A, Bedawy E, Schormann W, Hermes M, et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci USA. 2010; 107(23):10371-10376. Supporting Information. doi:10.1073/pnas.0909374107PMID: 20484673.
8. Schwen LO, Krauss M, Niederalt C, Gremse F, Kiessling F, Schenk A, et al. Spatio-Temporal Simulation of First Pass Drug Perfusion in the Liver. PLoS Comput Biol. 2014; 10(3):1-18. E1003499. doi:10.1371/journal.pcbi.1003499.
9. Couinaud C. Le Foie: Études anatomiques et chirurgicales. Paris: Masson; 1957.
10. Fiebig T, Boll H, Figueiredo G, Kerl HU, Nittka S, Groden C, et al. Three-dimensional in vivo imaging of the murine liver: A micro-computed tomography-based anatomical study. PLOS ONE. 2012; 7(2): E31179. doi:10.1371/journal.pone.0031179 PMID: 22363574.
11. Fasel JHD, Schenk A. Concepts for Liver Segment Classification: Neither Old Ones nor New Ones, but a Comprehensive One. J Clin Imaging Sci. 2013; 3(4):48. doi:10.4103/2156-7514.120803 PMID: 24228216.
12. Gebhardt R. Metabolic zonation of the liver: Regulation and implications for liver function. Pharmacol Ther. 1992; 53(3):275-354. doi:10.1016/0163-7258(92)90055-5 PMID: 1409850.
13. Gebhardt R, Matz-Soja M. Liver zonation: Novel aspects of its regulation and its impact on homeostasis. World J Gastroenterol. 2014; 20(26):8491-8504. doi:10.3748/wjg.v20.i26.8491 PMID: 25024605.
14. Homeyer A, Schenk A, Arlt J, Dahmen U, Dirsch O, Hahn HK. Practical quantification of necrosis in histological whole-slide images. Comput Med Imag Grap. 2013; 37(4):313-322. doi: 10.1016/j. compmedimag.2013.05.002.
15. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, et al. A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks. Front Physiol. 2011; 2(4):1-10.
16. Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2012; 40 (5):892-901. doi:10.1124/dmd.111.043174 PMID: 22293118.
17. Lippert J, Brosch M, von Kampen O, Meyer M, Siegmund HU, Schafmayer C, et al. A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development. CPT Pharmacometrics Syst Pharmacol. 2012; 1(10):e13. doi:10.1038/psp.2012.14 PMID: 23835795.
18. Maharaj AR, Edginton AN. Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development. CPT Pharmacometrics Syst Pharmacol. 2014; 3(11):1-13. doi: 10.1038/psp. 2014.45.
19. Thiel C, Schneckener S, Krauss M, Ghallab A, Hofmann U, Kanacher T, et al. A Systematic Evaluation of the Use of Physiologically Based Pharmacokinetic Modeling for Cross-Species Extrapolation. J Pharmaceut Sci. 2014; 104:191-206. doi: 10.1002/jps.24214.
20. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977; 5 (6):625-653. PMID: 599411.
21. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim: A physiologically based pharmacokinetic 'whole-body' model. BIOSILICO. 2003; 1(4):121-124. doi: 10.1016/S1478-5382(03) 02342-4.
22. Upton RN. The two-compartment recirculatory pharmacokinetic model-an introduction to recirculatory pharmacokinetic concepts. Br J Anaesth. 2004; 92(4):475-484. doi: 10.1093/bja/aeh089 PMID: 14766714.
23. Weiss M, Krejcie TC, Avram MJ. A physiologically based model of hepatic ICG clearance: Interplay between sinusoidal uptake and biliary excretion. Eur J Pharm Sci. 2011; 44:359-365. doi:10.1016/j.ejps.2011.08.018 PMID: 21893195.
24. Pond SM, Tozer TN. First-pass elimination basic concepts and clinical consequences. Clin Pharmacokinet. 1984; 9(1):1-25. doi:10.2165/00003088-198409010-00001 PMID: 6362950.
25. Jungermann K. Zonation of metabolism and gene expression in liver. Histochem Cell Biol. 1995; 103 (2):81-91. doi:10.1007/BF01454004 PMID: 7634156.
26. Lindros KO. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen Pharmacol Vasc S. 1997; 28(2):191-196. doi: 10.1016/S0306-3623(96)00183-8.
27. Häussinger D, Sies H, Gerok W. Functional hepatocyte heterogeneity in ammonia metabolism: The intercellular glutamine cycle. Journal of Hepatol. 1985; 1(1):3-14. doi: 10.1016/S0168-8278(85) 80063-5.
28. Weber LWD, Boll M, Stampfl A. Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model. Crit Rev Toxicol. 2003; 33(2):105-136. doi:10.1080/713611034PMID: 12708612.
29. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012; 32(1):3-13. doi:10.1055/s-0032-1306421 PMID: 22418883.
30. Abu-Zahra TN, Pang KS. Effect of zonal transport and metabolism on hepatic removal: Enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metab Dispos. 2000; 28(7):807-813. PMID: 10859155.
31. Anissimov YG, Roberts MS. A compartmental model of hepatic disposition kinetics: 1. Model development and application to linear kinetics. J Pharmacokinet Pharmacodyn. 2002; 29(2):131-156. doi:10.1023/A:1019703607647 PMID: 12361240.
32. Rani HP, Sheu TWH, Chang TM, Liang PC. Numerical investigation of non-Newtonian microcirculatory blood flow in hepatic lobule. J Biomech. 2006; 39(3):551-563. doi:10.1016/j.jbiomech.2004.11.029 PMID: 16389096.
33. Wambaugh J, Shah I. Simulating microdosimetry in a virtual hepatic lobule. PLoS Comput Biol. 2010; 6(4):e1000756. doi:10.1371/journal.pcbi.1000756 PMID: 20421935.
34. Schliess F, Hoehme S, Henkel SG, Ghallab A, Driesch D, Böttger J, et al. Integrated metabolic spatial- Temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatol. 2014; 60(6):2040-2051. doi: 10.1002/hep.27136.
35. Debbaut C, Vierendeels J, Siggers JH, Repetto R, Monbaliu D, Segers P. A 3D porous media liver lobule model: The importance of vascular septa and anisotropic permeability for homogeneous perfusion. Comput Meth Biomech Biomed Eng. 2014; 17(12):1295-1310. doi: 10.1080/10255842.2012.744399.
36. Siggers JH, Leungchavaphongse K, Ho CH, Repetto R. Mathematical model of blood and interstitial flow and lymph production in the liver. Biomech Model Mechanobiol. 2014; 13(2):363-378doi:10.1007/s10237-013-0516-x PMID: 23907149.
37. Ricken T, Werner D, Holzhütter HG, König M, Dahmen U, Dirsch O. Modeling function-perfusion behavior in liver lobules including tissue, blood, glucose, lactate and glycogen by use of a coupled two-scale PDE-ODE approach. Biomech Model Mechanobiol. 2014;p. 1-22.
38. Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol. 2007; 13:33-43. doi: 10.1016/j.ejrad.2006.11.005.
39. Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis Heterogeneity in Nonalcoholic Steatohepatitis and Hepatitis C Virus Needle Core Biopsy Specimens. Am J Clin Pathol. 2005; 123:382-387. doi:10.1309/EY72F1EN9XCB1KXX PMID: 15716234.
40. Bedossa P, Dargère D, Paradis V. Sampling Variability of Liver Fibrosis in Chronic Hepatitis C. Hepatol. 2003; 38:1449-1457. doi: 10.1016/j.hep.2003.09.022.
41. Maharaj B, Leary WP, Naran AD, Maharaj RJ, Cooppan RM, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986; 327 (8480):523-525. doi: 10.1016/S0140-6736(86)90883-4.
42. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 1989; 49(23):6449-6465. Available from: http://cancerres.aacrjournals.org/content/49/23/6449. PMID: 2684393.
43. Avila MA, Berasain C, Torres L, Martín-Duce A, Corrales FJ, Yang H, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol. 2000; 33(6):907-914. doi:10.1016/S0168-8278(00)80122-1 PMID: 11131452.
44. Tanaka T, Arai Y, Inaba Y, Matsueda K, Aramaki T, Takeuchi Y, et al. Radiologic placement of sidehole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2003; 14 (1):63-68. doi:10.1097/01.RVI.0000052292.26939.59 PMID: 12525587.
45. Gasselhuber A, Dreher MR, Partanen A, Yarmolenko PS, Woods D, Wood BJ, et al. Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: Computational modelling and preliminary in vivo validation. Int J Hyperthermia. 2012; 28(4):337-348. doi:10.3109/02656736.2012.677930 PMID: 22621735.
46. Bass L, Robinson P, Bracken AJ. Hepatic elimination of flowing substrates: The distributed model. J Theoret Biol. 1978; 72(1):161-184. doi: 10.1016/0022-5193(78)90023-1.
47. Forker EL, Luxon B. Hepatic transport kinetics and plasma disappearance curves: distributed modeling versus conventional approach. Am J Physiol Gastrointest Liver Physiol. 1978; 235(6):G648- G660. Available from: http://ajpendo.physiology.org/content/235/6/E648.full.
48. Holzhütter HG. Personal communication.
49. LaBarbera M. Principles of Design of Fluid Transport Systems in Zoology. Science. 1990; 249:992- 1000. doi:10.1126/science.2396104 PMID: 2396104.
50. Truskey GA, Yuan F, Katz DF. Transport Phenomena in Biological Systems (International Edition). 2nd ed. Pearson; 2010.
51. Holzhütter HG, Drasdo D, Preusser T, Lippert J, Henney AM. The Virtual Liver: A Multidisciplinary, Multi-level Challenge for Systems Biology. Wiley Interdiscip Rev Syst Biol Med. 2012; 4(3):221-235. doi:10.1002/wsbm.1158 PMID: 22246674.
52. Krauss M, Schaller S, Borchers S, Findeisen R, Lippert J, Kuepfer L. Integrating Cellular Metabolism into a Multiscale Whole-Body Model. PLoS Comput Biol. 2012; 8(10):e1002750. doi:10.1371/journal.pcbi.1002750 PMID: 23133351.
53. Hunt CA, Ropella GEP, Yan L, Hung DY, Roberts MS. Physiologically based synthetic models of hepatic disposition. J Pharmacokinet Pharmacodyn. 2006; 33(6):737-772. doi:10.1007/s10928-006-9031-3 PMID: 17051440.
54. Kuepfer L. Towards whole-body systems physiology. Mol Syst Biol. 2010; 6(1). doi:10.1038/msb.2010.70PMID: 20823847.
55. Pang KS, Durk MR. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn. 2010; 37(6):591-615. doi:10.1007/s10928-010-9185-x PMID: 21153869.
56. Gores GJ, Kost LJ, LaRusso NF. The isolated perfused rat liver: conceptual and practical considerations. Hepatol. 1986; 6(3):511-517. doi: 10.1002/hep.1840060331.
57. Bessems M, 't Haard NA, Tolba R, Doorschodt BM, Leuvenink HGD, Ploeg RJ, et al. The isolated perfused rat liver: standardization of a time-honoured model. Lab Anim. 2006; 40(3):236-246. doi:10.1258/002367706777611460 PMID: 16803641.
58. Cohen SD, Hindmarsh AC. CVODE, a stiff/nonstiff ODE solver in C. Comput Phys. 1996; 10(2):138- 143. doi: 10.1063/1.4822377.
59. Willmann S, Thelen K, Lippert J. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim1. J Pharm Pharmacol. 2012; 64(7):997-1007. doi:10.1111/j.2042-7158.2012.01534.x PMID: 22686345.
60. Russell TF, Celia MA. An overview of research on Eulerian-Lagrangian Localized Adjoint Methods (ELLAM). Adv Water Resour. 2002; 25(8-12):1215-1231. doi: 10.1016/S0309-1708(02)00104-5.
61. Fehlberg E. Klassische Runge-Kutta-Formeln vierter und niedrigerer Ordnung mit Schrittweiten-Kontrolle und ihre Anwendung auf Wärmeleitungsprobleme. Comput. 1970; 6:61-70. doi: 10.1007/BF02241732.
62. Krejcie TC, Henthorn TK, Shanks CA, Avram MJ. A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs. J Pharmacol Exp Ther. 1994; 269(2):609-616. PMID: 8182527.
63. Parker GJM, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, et al. Experimentally- derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med. 2006; 56(5):993-1000. doi: 10.1002/mrm. 21066 PMID: 17036301.
64. Börner W, Moll E, Schröder J, Rau HP. Die Abhängigkeit der Kreislaufzeit von Alter, Geschlecht und Körperlänge. Arch Kreislaufforsch. 1964; 43(4):221-235. doi: 10.1007/BF02120035.
65. Hairer E, Wanner G. Solving Ordinary Differential Equations. II. Stiff and Differential-Algebraic Problems. vol. 14 of Springer Series in Computational Mathematics. 2nd ed. Springer; 1996.
66. Shampine LF, Reichelt MW. The matlab ODE suite. SIAM J Sci Comput. 1997; 18(1):1-22. doi: 10. 1137/S1064827594276424.
67. Brown PN, Byrne GD, Hindmarsh AC. VODE: A variable-coefficient ODE solver. SIAM J Sci and Stat Comput. 1989; 10(5):1038-1051. doi: 10.1137/0910062.
68. Hindmarsh AC, Brown PN, Grant KE, Lee SL, Serban R, Shumaker DE, et al. SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers. ACM Trans Math Software. 2005; 31(3):363- 396. doi: 10.1145/1089014.1089020.
69. Palsson BO, Lightfoot EN. Mathematical modelling of dynamics and control in metabolic networks. I. On Michaelis-Menten kinetics. J Theoret Biol. 1984; 111(2):273-302. doi: 10.1016/S0022-5193(84) 80211-8.
70. Puhl G, Schaser KD, Vollmar B, Menger MD, Settmacher U. Noninvasive in vivo analysis of the human hepatic microcirculation using orthogonal polorization spectral imaging. Transplant. 2003; 75 (6):756-761. doi: 10.1097/01.TP.0000056634.18191.1A.
71. Koo A, Liang IYS, Cheng KK. The terminal hepatic microcirculation in the rat. Exp Physiol. 1975; 60 (4):261-266. http://ep.physoc.org/content/60/4/261.short. doi: 10.1113/expphysiol.1975.sp002320.
72. Müller M, Keimling R, Lang S, Pauli J, Dahmen U, Dirsch O. Estimating Blood Flow Velocity in Liver Vessels. In: Meinzer HP, Deserno TM, Handels H, Tolxdorff T, editors. Bildverarbeitung für die Medizin 2009. Informatik Aktuell. Springer; 2009. p. 36-40.
73. Lautt WW. Regulatory processes interacting to maintain hepatic blood flow constancy: Vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res. 2007; 37:891-903. doi:10.1111/j.1872-034X.2007.00148.x PMID: 17854463.
74. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: The hepatic arterial buffer response revisited. World J Gastroenterol. 2010; 16(28):6046-6057. doi:10.3748/wjg.v16.i48.6046 PMID: 21182219.
75. Gupta SC. Fluid Mechanics and Hydraulic Machines. Pearson Education India; 2006.
76. Fåhræus R, Lindqvist T. The Viscosity of the Blood in Narrow Capillary Tubes. Am J Physiol. 1931; 96 (3):562-568.
77. Schwen LO, Wei W, Gremse F, Ehling J, Wang L, Dahmen U, et al. Algorithmically Generated Rodent Hepatic Vascular Trees in Arbitrary Detail. J Theoret Biol. 2015; 365:289-300. doi: 10.1016/j.jtbi. 2014.10.026.
78. Selle D, Preim B, Schenk A, Peitgen HO. Analysis of vasculature for liver surgical planning. IEEE Trans Med Imaging. 2002; 21(11):1344-1357. doi:10.1109/TMI.2002.801166 PMID: 12575871.
79. Schwen LO, Preusser T. Analysis and Algorithmic Generation of Hepatic Vascular Systems. Int J Hepatol. 2012;(Article ID 357687):1-17. doi:10.1155/2012/357687.
80. Schreiner W. Concepts and Features of Arterial Tree Models Generated by Constrained Constructive Optimization. Comm Theoret Biol. 2001; 6(1):103-136.
81. Evans WH, Martin PEM. Gap junctions: structure and function (Review). Molec Membrane Biol. 2002; 19(2):121-136. doi: 10.1080/09687680210139839.
82. Cabrera M, Frevert U. Novel in vivo imaging techniques for the liver microvasculature. Intravit. 2012; 1 (2):107-114. doi: 10.4161/intv.23423.
83. Wang H, Ewing RE, Qin G, Lyons SL, Al-Lawatia M, Man S. A Family of Eulerian-Lagrangian Localized Adjoint Methods for Multi-dimensional Advection-Reaction Equations. J Comput Phys. 1999; 152:120-163. doi: 10.1006/jcph.1999.6239.
84. Younes A, Fahs M, Ackerer P. A new approach to avoid excessive numerical diffusion in Eulerian- Lagrangian methods. Comm Numer Methods Eng. 2008; 24(11):897-910. doi: 10.1002/cnm.996.
85. Celia MA, Russell TF, Herrera I, Ewing RE. An Eulerian-Lagrangian localized adjoint method for the advection-diffusion equation. Adv Water Resour. 1990; 13(4):187-206. doi: 10.1016/0309-1708(90) 90041-2.
86. Wang H, Ewing RE, Russell TF. Eulerian-Lagrangian localized adjoint methods for convection-diffusion equations and their convergence analysis. IMA J Numer Anal. 1995; 15:405-459. doi: 10.1093/imanum/15.3.405.
87. Ewing RE, Wang H. A summary of numerical methods for time-dependent advection-dominated partial differential equations. J Comput Appl Math. 2001; 128(1):423-445. doi: 10.1016/S0377-0427(00) 00522-7.
88. Gross ES, Koseff JR, Monismith SG. Evaluation of Advective Schemes for Estuarine Salinity Simulation. J Hydraul Eng. 1999; 125:32-46. doi: 10.1061/(ASCE)0733-9429(1999)125:1(32).
89. Binning P, Celia MA. A forward particle tracking Eulerian-Lagrangian Localized Adjoint Method for solution of the contaminant transport equation in three dimensions. Adv Water Resour. 2002; 25:147- 157. doi: 10.1016/S0309-1708(01)00051-3.
90. Neubauer T, Bastian P. On a monotonicity preserving Eulerian-Lagrangian localized adjoint method for advection-diffusion equations. Adv Water Resour. 2005; 28:1292-1309. doi: 10.1016/j.advwatres. 2005.04.010.
91. Wang H. A Family of ELLAM Schemes for Advection-Diffusion-Reaction Equations and their Convergence Analyses. Numer Methods Partial Differential Equations. 1998; 14(6):739-780. doi:10.1002/(SICI)1098-2426(199811)14:6%3C739::AID-NUM3%3E3.3.CO;2-0.
92. Wang H, Shi X, Ewing RE. An ELLAM scheme for multidimensional advection-reaction equations and its optimal-order error estimates. SIAM J Numer Anal. 2001; 38(6):1846-1885. doi: 10.1137/S0036142999362389.
93. Våg JE, Wang H, Dahle HK. Eulerian-Lagrangian localized adjoint methods for systems of nonlinear advective-diffusive-reactive transport equations. Adv Water Resour. 1996; 19(5):297-315. doi: 10. 1016/0309-1708(96)00006-1.
94. AG Rumpf, Institute for Numerical Simulation, University of Bonn. QuocMesh software library, version 1.3; 2011. Available from: http://numod.ins.uni-bonn.de/software/quocmesh/index.html.
95. Galassi M, Davies J, Theiler J, Gough B, Jungman G, Alken P, et al. GNU Scientific Library Reference Manual Edition 1.16; 2013. Available from: http://www.gnu.org/software/gsl/.
96. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical Recipies in C. 2nd ed. Cambridge University Press; 1992.
97. Hairer E, Wanner G, Nørsett SP. Solving Ordinary Differential Equations. I. Nonstiff Problems. vol. 8 of Springer Series in Computational Mathematics. 2nd ed. Springer; 1993.
98. Yoon YJ, Chang S, Kim OY, Kang BK, Park J, Lim JH, et al. Three-Dimensional Imaging of Hepatic Sinusoids in Mice Using Synchrotron Radiation Micro-Computed Tomography. PLOS ONE. 2013; 8 (7):e68600. doi:10.1371/journal.pone.0068600 PMID: 23861925.
99. Teutsch HF, Schuerfeld D, Groezinger E. Three-Dimensional Reconstruction of Parenchymal Units in the Liver of the Rat. Hepatol. 1999; 29:494-505. doi: 10.1002/hep.510290243.
100. Miller DL, Zanolli CS, Gumucio JJ. Quantitative Morphology of the Sinusoids of the Hepatic Acinus. Gastroenterol. 1979; 76(5):965-969.
101. Mallat S. A Wavelet Tour of Signal Processing. 2nd ed. Academic Press; 1999.
102. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132(2):112-117. doi:10.7326/0003-4819-132-2-200001180-00004 PMID: 10644271.
103. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther. 2005; 22(s2):64-70. doi:10.1111/j.1365-2036.2005.02600.x PMID: 16225477.
104. Hijmans BS, Grefhorst A, Oosterveer MH, Groen AK. Zonation of glucose and fatty acid metabolism in the liver: Mechanism and metabolic consequences. Biochimie. 2014; 96:121-129. doi:10.1016/j.biochi.2013.06.007 PMID: 23792151.
105. Capitan V, Petit JM, Aho S, Lefevre PH, Favelier S, Loffroy R, et al. Macroscopic heterogeneity of liver fat: An MR-based study in type-2 diabetic patients. Eur Radiol. 2012; 22(10):2161-2168. doi:10.1007/s00330-012-2468-4 PMID: 22562090.
106. Buechler C, Weiss TS. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab. 2011; 12(1):24-34. doi:10.2174/138920011794520035 PMID: 21222589.
107. Li P, Robertson TA, Thorling CA, Zhang Q, Fletcher LM, Crawford DHG, et al. Hepatic Pharmacokinetics of Cationic Drugs in a High-Fat Emulsion-Induced Rat Model of Nonalcoholic Steatohepatitis. Drug Metab Dispos. 2011; 39(4):571-579. doi:10.1124/dmd.110.036806 PMID: 21245286.
108. Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of Hepatic Microcirculation in Fatty Liver. Microcirc. 2003; 10(6):447-456. doi: 10.1038/sj.mn.7800206.
109. Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int. 2010; 30(3):365-375. doi:10.1111/j.1478-3231.2009.02136.x PMID: 19840249.
110. Sun J. Induction of fatty liver in Lew rats using different diets [Dissertation]. University of Duisburg- Essen; 2011.
111. Franzén LE, Ekstedt M, Kechagias S, Bodin L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: A comparison to stereological point counting. Mod Pathol. 2005; 18 (7):912-916. doi:10.1038/modpathol.3800370 PMID: 15920560.
112. Matsumoto M, Nishimura T. Mersenne Twister: A 623-Dimensionally Equidistributed Uniform Pseudo-Random Number Generator. ACM Trans Mod Comput Simul. 1998; 8(1):3-30. doi: 10.1145/272991.272995.
113. Hoehme S, Brulport M, Bauer A, Bedawy E, Schormann W, Hermes M, et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci USA. 2010; 107(23):10371-10376. doi:10.1073/pnas.0909374107PMID:20484673.
114. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatol. 2005; 42 (6):1364-1372. doi: 10.1002/hep.20948.
115. Shestopaloff YK. Method for Finding Metabolic Properties Based on the General Growth Law. Liver Examples. A General Framework for Biological Modeling. PLOS ONE. 2014; 9(6):e99836. doi:10.1371/journal.pone.0099836PMID: 24940740.
116. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiol. 1985; 62(3):310-324. Available from: http://journals.lww.com/anesthesiology/Citation/1985/03000/MidazolamPharmacology-and-Uses-.17.aspx doi: 10.1097/00000542-198503000-00017.
117. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996; 59(5):491-502. Available from: http://www.nature.com/clpt/journal/v59/n5/abs/clpt1996411a.htmldoi:10.1016/S0009-9236(96)90177-0 PMID: 8646820.
118. Allen JW, Bhatia SN. Formation of steady-state oxygen gradients in vitro: Application to liver zonation. Biotechnol Bioeng. 2003; 82(3):253-262. doi:10.1002/bit.10569 PMID: 12599251.
119. Oyama T, Sugio K, Uramoto H, Kawamoto T, Kagawa N, Nadaf S, et al. Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci. 2007; 12:2299-2308. doi:10.2741/2232PMID: 17127240.
120. Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005; 59(6):691-704. doi:10.1111/j.1365-2125.2004.02225.x PMID: 15948934.
121. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0-the human metabolome database in 2013. Nucleic Acids Res. 2013; 41(D1):D801-D807. doi:10.1093/nar/gks1065 PMID: 23161693.
122. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and Bioavailability of Midazolam in Man. Br J Clin Pharmacol. 1983; 16(S1):43S-49S doi:10.1111/j.1365-2125.1983.tb02270.x PMID: 6138080.
123. Brill MJE, van Rongen A, Houwink API, Burggraaf J, van Ramshorst B, Wiezer RJ, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: A comparison with healthy volunteers. Clin Pharmacokinet. 2014; 53(10):931-941. doi:10.1007/s40262-014-0166-x PMID: 25141974.
124. Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol Vasc S. 1996; 27(2):245-249. doi: 10.1016/0306-3623(95)02014-4.
125. Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A. Caffeine as an analgesic adjuvant. J Am Med Assoc. 1984; 251(13):1711-1718. doi: 10.1001/jama.1984.03340370043028.
126. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. New Engl J Med. 2006; 354(20):2112-2121. doi:10.1056/NEJMoa054065 PMID: 16707748.
127. Buters JTM, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenet Genomics. 1996; 6(4):291-296. doi: 10.1097/00008571-199608000-00002.
128. Braeuning A, Sanna R, Huelsken J, Schwarz M. Inducibility of drug-metabolizing enzymes by xenobiotics in mice with liver-specific knockout of Ctnnb1. Drug Metab Dispos. 2009; 37(5):1138-1145. doi:10.1124/dmd.108.026179 PMID: 19237511.
129. Atkinson AJ Jr, Kushner W. Clinical Pharmacokinetics. Annu Rev Pharmacol Toxicol. 1979; 19 (1):105-127. doi:10.1146/annurev.pa.19.040179.000541 PMID: 378099.
130. Tanaka E, Ishikawa A, Misawa S. Changes in Caffeine, Lidocaine and Trimethadione Metabolism in Carbon Tetrachloride-Intoxicated Rats as Assessed by a "Cocktail" Study. Pharmacol Toxicol. 1994; 75(3-4):150-153. doi:10.1111/j.1600-0773.1994.tb00338.x PMID: 7800655.
131. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 2004; 30(5):398-408. doi:10.1016/S1262-3636(07)70133-7 PMID: 15671906.
132. Song SH, McIntyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC. Direct Measurement of Pulsatile Insulin Secretion from the Portal Vein in Human Subjects. J Clin Endocrinol Metab. 2000; 85 (12):4491-4499. doi:10.1210/jc.85.12.4491 PMID: 11134098.
133. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005; 54(6):1649-1656. doi:10.2337/diabetes.54.6.1649 PMID: 15919785.
134. Matveyenko AV, Veldhuis JD, Butler PC. Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein. Am J Physiol Endocrinol Metab. 2008; 295(3):E569-E574. doi:10.1152/ajpendo.90335.2008PMID: 18577690.
135. Pørksen N. The in vivo regulation of pulsatile insulin secretion. Diabetologia. 2002; 45(1):3-20. doi:10.1007/s125-002-8240-x PMID: 11845219.
136. Pørksen N, Hollingdal M, Juhl C, Butler P, Veldhuis JD, Schmitz O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes. 2002; 51(suppl 1):S245-S254. PMID: 11815487.
137. Bertram R, Sherman A, Satin LS. Metabolic and electrical oscillations: partners in controlling pulsatile insulin secretion. Am J Physiol Endocrinol Metab. 2007; 293(4):E890-E900. doi:10.1152/ajpendo.00359.2007 PMID: 17666486.
138. Kreutz C. Statistical Approaches for Molecular and Systems Biology [Dissertation]. Albert-Ludwigs- Universität Freiburg; 2011. http://nbn-resolving.de/urn:nbn:de:bsz:25-opus-84047.
139. Misbin RI, Merimee TJ, Lowenstein JM. Insulin removal by isolated perfused rat liver. Am J Physiol. 1976; 230(1):171-177. PMID: 1251902.
140. Sedaghat AR, Sherman A, Quon MJ. A Mathematical Model of Metabolic Insulin Signaling Pathways. Am J Physiol Endocrinol Metab. 2002; 283(5):E1084-E1101. doi:10.1152/ajpendo.00571.2001 PMID: 12376338.
141. Schaller S, Willmann S, Lippert J, Schaupp L, Pieber TR, Schuppert A, et al. A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System. CPT Pharmacometrics Syst Pharmacol. 2013; 2(8):e65. doi:10.1038/psp.2013.40 PMID: 23945606.
142. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: A marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012; 92 (1):50-61. doi:10.1038/clpt.2012.65 PMID: 22644330.
143. Yoon M, Campbell JL, Andersen ME, Clewell HJ. Quantitative in vitro to in vivo extrapolation of cellbased toxicity assay results. Crit Rev Toxicol. 2012; 42(8):633-652. doi:10.3109/10408444.2012.692115 PMID: 22667820.
144. Webborn PJH, Parker AJ, Denton RL, Riley RJ. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects. Xenobiotica. 2007; 37(10-11):1090- 1109. doi:10.3109/00498250701557266 PMID: 17968738.
145. Chow ECY, Pang SK. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab. 2013; 14(1):57-79. doi:10.2174/138920013804545124 PMID: 22935069.
146. Schwen LO, Homeyer A, Schwier M, Gremse F, Schenk A, Kuepfer L, et al. Multiscale Simulation of Zonated Metabolism in Steatotic Livers; 2014. Presentation at VPH 2014. http://seek.virtuelle-leber.de/presentations/703.
147. Schwen LO, Homeyer A, Schwier M, Dahmen U, Dirsch O, Schenk A, et al. Zonated Quantification of Steatosis in an Entire Mouse Liver. 2015; submitted.
148. Bois FY, Jamei M, Clewell HJ. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicol. 2010; 278(3):256-267. doi: 10.1016/j.tox.2010.06.007.
149. Drasdo D, Bode J, Dahmen U, Dirsch O, Dooley S, Gebhardt R, et al. The virtual liver: state of the art and future perspectives. Arch Toxicol. 2014; 88(12):2071-2075. doi:10.1007/s00204-014-1384-6 PMID: 25331938.